Drug Trial Radar · NCT04632992
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Jan 13, 2021
Primary completion
Dec 4, 2023
Study completion Feb 27, 2024
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers. Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.
Conditions
- Advanced Unresectable or Metastatic Solid Malignancy
Interventions
EntrectinibDrug
Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
InavolisibDrug
Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
AlectinibDrug
Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
IpatasertibDrug
Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
AtezolizumabDrug
Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
Trastuzumab EmtansineDrug
Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxfDrug
PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
TucatinibDrug
Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
Investigator's Choice of ChemotherapyDrug
Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
PaclitaxelDrug
The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
TiragolumabDrug
Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
PralsetinibDrug
Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) TumorsTime frame: Up to 32 months
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Alaska Oncology and Hematology
Anchorage, Alaska
Arizona Clinical Research Ctr
Oro Valley, Arizona
Genesis Cancer Center
Hot Springs, Arkansas
California Cancer Associates for Research and Excellence - Encinitas
Encinitas, California
Los Angeles Hematology Oncology Medical Group
Los Angeles, California
Pacific Cancer Care - Monterey
Monterey, California
Kaiser Permanente - San Francisco Medical Center
San Francisco, California
Sarcoma Oncology Center
Santa Monica, California
Kaiser Permanente Medical Ctr
Vallejo, California
Ventura County Hematology Oncology Specialists
Ventura, California
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut
SCRI Florida Cancer Specialists South
Fort Myers, Florida
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida
Florida Cancer Specialists - PAN - SCRI - PPDS
Tallahassee, Florida
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida
St Luke?s Cancer Institute
Boise, Idaho
Hematology and Oncology Clinic
Baton Rouge, Louisiana
Saint Agnes Hospital - Baltimore - Hunt - PPDS
Baltimore, Maryland
Ascension St. John Hospital
Detroit, Michigan
Frontier Cancer Center and Blood Institute
Billings, Montana
Southeast Nebraska Cancer Center
Lincoln, Nebraska
New Jersey Hematology Oncology Associates LLC
Brick, New Jersey
Astera Cancer Care East Brunswick
East Brunswick, New Jersey
Central Park Hematology and Oncology
New York, New York
Eastchester Center for Cancer Care
The Bronx, New York
New York Cancer & Blood Specialists
The Bronx, New York
Messino Cancer Centers
Asheville, North Carolina
Gabrail Cancer Center
Canton, Ohio
Tri County Hematologyoncology
Canton, Ohio
SCRI Mark H. Zangmeister Center
Columbus, Ohio
Kaiser Permanente Center For Health Research
Portland, Oregon
Sarah Cannon Research Institute / Tennessee Oncology
Chattanooga, Tennessee
The West Clinic, PC dba West Cancer Center
Memphis, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
The Center for Cancer and Blood Disorders - PPDS
Fort Worth, Texas
Mays Cancer Center at UT Health San Antonio MD Anderson Cancer
San Antonio, Texas
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Northwest Medical Specialties B
Federal Way, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.